所有产品
  • 抗体
  • 试剂盒
  • 多肽
  • 蛋白
  • 生化试剂
  • 组织芯片
EN
cAMP/ cGMP/ Protein A/ β-Actin/ BSA/ Ddx4/ APOE/ TAU pT181/ TAU pT217/ Tau 1-441/ Aβ1-40/ Aβ1-42/ α-Syn/ GFAP/ IL/ CD/ 标记试剂盒/ GFP/ Flag/ 多肽合成服务/ /
抗体药类似物
当前位置：首页 > 产品中心 > 抗体 > 抗体药类似物
产品中心
Product Center
Research Grade Risankizumab
All
Bioactivity
SDS-PAGE
Western blot
  • Catalog： TD-HV466016
  • Clonality： Monoclonal
  • Application： ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Synonyms： BI655066, risankizumab-rzaa, 1612838-76-2
  • 规格：
    询价
  • 价格：
    ¥100ug
定制服务咨询
详细相关信息
FAQ
实验方案
参考文献
  • Catalog No.
    TD-HV466016
  • Description
    Risankizumab(TD-HV466016) is a research-grade recombinant antibody targetingSGRF. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
  • Species reactivity
    Human
  • Applications
    ELISA, Bioactivity: FACS, Functional assay, Research in vivo
  • Host species
    Humanized
  • Isotype
    IgG1-kappa
  • Clonality
    Monoclonal
  • Target
    SGRF, IL-23-A, IL-23 subunit alpha, Interleukin-23 subunit p19, IL23A, Interleukin-23 subunit alpha, IL-23p19
  • Endotoxin level
    Please contact the lab for this information.
  • Purity
    >95% purity as determined by SDS-PAGE.
  • Purification
    Protein A/G purified from cell culture supernatant.
  • Accession
    Q9NPF7
  • Form
    Liquid
  • Storage buffer
    0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
  • Stability and Storage
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
  • Alternate Names
    BI655066, risankizumab-rzaa, 1612838-76-2
  • Background
    Mirikizumab (Eli Lilly and Company), Risankizumab (Boehringer Ingelheim and AbbVie), Tildrakizumab (Sun Pharma), Brazikumab (AstraZeneca), and Guselkumab (Janssen Biotech Inc.) are other drugs which target IL-23 and received the FDA approval for the treatment of psoriasis.
  • Caption
    SEC-HPLC detection for Research Grade Risankizumab. ### Detects IL23A in indirect ELISA　　|　SDS-PAGE for Research Grade Risankizumab.　　|　Western blot analysis was performed using anti-IL23A monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant human IL23A (Catalog No:TD-HV466011)Lane 2:negative control
  • Note
    For research use only. Not suitable for clinical or therapeutic use.